NCT03962543 2026-04-08
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
Clinical Trials
16 trialsNCT04924608 2026-03-23
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT03531814 2024-06-11
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT02101736 2023-05-24
NF105-CABO
University of Alabama at Birmingham
Phase 2 Completed
NCT02471339 2022-06-14
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT02124772 2021-07-14
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Novartis
Phase 1/2 Completed
NCT00030264 2018-08-08
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Children's Hospital of Philadelphia
Phase 2 Completed
NCT00076102 2018-04-23
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01402817 2018-03-14
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Indiana University
Phase 2 Terminated
NCT00396019 2017-11-06
Study of PEG-Intron for Plexiform Neurofibromas
University of Pittsburgh
Phase 2 Completed
NCT00326872 2017-08-18
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01275586 2017-04-12
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Indiana University
Phase EARLY_PHASE1 Completed
NCT01365468 2016-05-12
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Novartis
Phase 2 Terminated
NCT00060008 2014-04-04
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
Children's Hospital of Philadelphia
Phase NA Terminated